Tissue Engineering and Regenerative Medicine (TERM)
Uppsala BIO led a taskforce and carried out national and international benchmarking on a key potentially curative therapy.
In 2010, 13 organisations from eight European regions launched the Tissue Engineering and Regenerative Medicine (TERM) project* supported by the Seventh Framework Program (FP7) ‘Regions of Knowledge’.
The TERM consortium emphasised the importance of regenerative medicine for both future healthcare development and economic growth in Europe. To contribute to the introduction of this potentially curative medicine as a therapy of choice for European patients, it promoted trans-regional cooperation in research and development, education and innovation support. Uppsala BIO led one of the taskforces and carried out regenerative medicine benchmarking on both national and international levels, which also proved to be important for internal operations.
A foundation established by Uppsala BIO to roll out BIO-X throughout Europe was not prioritised after the TERM project ended since Uppsala BIO had by then been assigned the task of a national BIO-X rollout.
*Project title: Linking research organisations in the fields of Tissue Engineering and Regenerative Medicine through European cooperation between regional research clusters.
Financing: EU FP7: Regions of Knowledge (Grant Agreement Number: 265546)
Project duration: 2010–2013
Contact: Malin Wiederholm, Uppsala BIO
Uppsala BIO’s role: Taskforce leader
Malin Wiederholm. Product Manager. (parental leave) “I am passionate about developing targeted innovation strategies, where market pull rather than technology push determines which innovations are funded and highlighted.”